According to CEO: ‘Demand across the industry not meeting our expectations.’ ...

Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology ...

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

I-MAB completed a workforce reduction as part of a Realignment Plan aimed at optimizing its operations following the pipeline reprioritization. The company reduced its workforce by approximately 27% ...